J.P. Morgan Maintains Their Hold Rating on Biogen Inc (BIIB)

In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on Biogen Inc (BIIB). The company’s shares closed yesterday at $226.09, close to its 52-week low of $216.12.

According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 0.7% and a 41.3% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.

Currently, the analyst consensus on Biogen Inc is a Hold with an average price target of $256.09, a 13.3% upside from current levels. In a report issued on May 22, Wedbush also initiated coverage with a Hold rating on the stock with a $231 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $388.67 and a one-year low of $216.12. Currently, Biogen Inc has an average volume of 2.55M.

Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BIIB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.